CureVac NV is a Pharmaceuticals company based in Germany. They are known for developing vaccines and therapies using messenger ribonucleic acid (mRNA). With an ESG risk score of 27.9, CureVac is considered a medium-risk investment. The company has collaborations with GSK for developing a second-generation covid vaccine. In addition to covid vaccines, CureVac also works on mRNA vaccines for influenza, rabies, and malaria. Moreover, they are exploring oncology and molecular therapies for tumors, liver, ocular, and lung diseases.